GSK_ Annual_Report

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 174 The Company has not granted any loans, provided guarantees or made investments pursuant to the provisions of Section 186 of the Companies Act, 2013, during the financial year 2021-22. There were no material changes and commitments affecting the financial position of the Company between the end of financial year and the date of this Report. Your Company has not accepted any deposits from the public during the year under review. There were no materially significant related party transactions made with the Promoters, Directors or Key Managerial Personnel which may have a potential conflict of Interest of the Company at large. No details as required under the provisions of Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are given, as there are no employees drawing remuneration in excess of the prescribed limits. There are no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company’s operations in future. The Company is 100 % subsidiary of GlaxoSmithKline Pharmaceuticals Limited (“Parent Company”) and all policies including Vigil Mechanism, Risk Management Policy and Internal Financial Control have been adopted on lines of parent Company. The Company does not have any manufacturing plant or office so Conservation of Energy & Technology Absorption is not applicable. The foreign exchange earnings for the year ended 31 March 2022 was 74,00.45 lakhs and foreign exchange outgo for the year ended 31 March 2022 was nil lakhs. The foreign exchange earnings for the period ended 31 March 2021 was 9,32.79 lakhs and foreign exchange outgo for the year ended 31 March 2021 was nil lakhs. ACKNOWLEDGEMENT The Directors expressed their appreciation for the support received from all other stakeholders, customers, suppliers, business partners and the government. For and on behalf of the Board of Directors S. Venkatesh Mumbai, 9 May 2022 Chairman Directors’ Report

GSK_ Annual_Report_2021-22